Minimal Change Disease clinical trials at UCSF
2 in progress, 1 open to eligible people
Minimal change disease leads to protein leakage from the kidneys. UCSF is conducting trials with various drugs like Frexalimab to assess their safety and effectiveness. The study involves participants between 16 and 75 years old.
Frexalimab, SAR442970, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
open to eligible people ages 16-75
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or primary minimal change disease (MCD). The purpose of this study is to measure the change in proteinuria and its impact…
San Francisco, California and other locations
Nephrotic Syndrome Study Network
Sorry, not currently recruiting here
Minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), and Membranous nephropathy (MN), generate an enormous individual and societal financial burden, accounting for approximately 12% of prevalent end stage renal disease (ESRD)…
San Francisco, California and other locations
Our lead scientists for Minimal Change Disease research studies include Paul Brakeman, MD, PhD.
Last updated: